Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Amphotericin B in Patients With Invasive Aspergillosis and Hepatic Dysfunction
NCT07337720Not yet recruiting
- Sponsor
- Southeast University
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Open-label, single-arm trial of liposomal amphotericin b in invasive aspergillosis (IA), sponsored by Southeast University. Primary endpoint: Overall Response Rate at 2 weeks. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
liposomal amphotericin b
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT07337720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337720.